Enquiry
British Pharmacopoeia (BP) 2026 – Multi-User Licence
The BP 2026 edition supersedes the BP 2025 and becomes legally effective on 1 January 2026 with all European Pharmacopoeia texts included. Updated annually, the British Pharmacopoeia (BP) is the only comprehensive collection of authoritative official standards for UK pharmaceutical substances and medicinal products.
It includes approximately 4,000 monographs, which are legally enforced by the Human Medicines Regulations 2012. Medicinal products or active pharmaceutical ingredients sold or supplied in the UK must comply with the relevant monograph. All monographs and requirements of the European Pharmacopoeia (Ph. Eur.) are reproduced in the BP, making the BP a convenient and fully comprehensive set of standards that can be used across Europe and internationally.
Multi User License
-
Optimised Access for Teams: Allows multiple licensed users to access BP Online simultaneously — ideal for national or global operations.
-
Flexible Licensing Models:
-
Standard MUL: Limited number of concurrent users within one country
-
Global Unlimited MUL: Unlimited concurrent users across multiple countries
-
Academic Unlimited MUL: Unlimited access for eligible educational institutions
-
-
Cost-Effective Shared Access: Pay only for expected concurrent users, rather than per seat.
-
Seamless Access Management:
-
Invite users via licence managers
-
Automatic access via domain recognition
-
Integration with Athens/Shibboleth (academic licences)
-
-
Trusted Worldwide: Used by pharmaceutical, regulatory, academic, and healthcare organisations.
New for the BP 2026 edition
- 19 new BP monographs and 34 new monographs reproduced from the 11th edition of the Ph. Eur., as amended by issues 11.6 to 11.8
- Two new appendices, four supplementary chapters, and six new infrared reference spectra have been added to the collection
- 12 new BPCRS have been produced and referenced
- 131 amended BP monographs
- All monographs from the Ph. Eur. 11th edition and Ph. Eur. issues up to 11.8
